Neurocrine Biosciences (NBIX) FCF Margin Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 213.00 |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 2,102.00 |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 180.00 |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 1,592.00 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -291.00 |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -2,476.00 |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 1,604.00 |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.09 Bn | 7.43 Bn | 397.90 Mn | -574.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,476.00 |
| Mar 31, 2026 | 4,765.00 |
| Dec 31, 2025 | 1,041.00 |
| Sep 30, 2025 | 237.00 |
| Jun 30, 2025 | -68,388.00 |
| Mar 31, 2025 | 2,339.00 |
| Dec 31, 2024 | 3,418.00 |
| Sep 30, 2024 | 908.00 |
| Jun 30, 2024 | -2,271.00 |
| Mar 31, 2024 | -1,374.00 |
| Dec 31, 2023 | -1,051.00 |
| Sep 30, 2023 | 5,045.00 |
| Jun 30, 2023 | 34.00 |
| Mar 31, 2023 | -4,456.00 |
| Dec 31, 2022 | -630.00 |
| Sep 30, 2022 | -1,717.00 |
| Jun 30, 2022 | 66,518.00 |
| Mar 31, 2022 | 6,778.00 |
| Dec 31, 2021 | -2,241.00 |
| Sep 30, 2021 | -3,175.00 |